Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psma-1007
- Development stage
- Unknown
- Lead developer
- ABX
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PróstaLumin is a radiopharmaceutical PET imaging agent containing the fluorine-18 labeled ligand PSMA-1007. It is designed to target the prostate-specific membrane antigen (PSMA), a protein highly overexpressed in prostate cancer cells. Developed and marketed by Biokosmos, PróstaLumin is used for the primary staging of high-risk prostate cancer patients prior to curative therapy and for the localization of suspected recurrence in patients with rising PSA levels. A key characteristic of PSMA-1007 is its predominant hepatobiliary excretion, which minimizes radioactivity in the urinary tract and enhances the visualization of lesions near the bladder and prostate bed compared to other PSMA-targeted tracers.
- Brand names
- PróstaLumin
- Other names
- [18F]PSMA-1007fluorine-18 psma-1007fluorine18 psma-1007fluorine 18 psma-1007
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on psma-1007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psma-1007.